These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26016732)

  • 1. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
    Mansur SA; Mieczkowska A; Bouvard B; Flatt PR; Chappard D; Irwin N; Mabilleau G
    J Cell Physiol; 2015 Dec; 230(12):3009-18. PubMed ID: 26016732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.
    Tatarkiewicz K; Hargrove DM; Jodka CM; Gedulin BR; Smith PA; Hoyt JA; Lwin A; Collins L; Mamedova L; Levy OE; D'Souza L; Janssen S; Srivastava V; Ghosh SS; Parkes DG
    Diabetes Obes Metab; 2014 Jan; 16(1):75-85. PubMed ID: 23859463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus.
    Mansur SA; Mieczkowska A; Flatt PR; Bouvard B; Chappard D; Irwin N; Mabilleau G
    Bone; 2016 Jun; 87():102-13. PubMed ID: 27062994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
    Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
    Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between bone and incretin hormones: A review.
    Mabilleau G
    Morphologie; 2017 Mar; 101(332):9-18. PubMed ID: 27423214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
    Martin CM; Irwin N; Flatt PR; Gault VA
    Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
    Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
    Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapy for the treatment of bone fragility in diabetes mellitus.
    Mabilleau G; Gobron B; Bouvard B; Chappard D
    Peptides; 2018 Feb; 100():108-113. PubMed ID: 29412811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
    Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
    Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
    Gault VA
    Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.